About Generic Drugs
A generic drug is a duplicate of brand-name drugs and has the same dosage form, active ingredient(s), potency, route of administration, quality, and intended use as that of branded drugs. Generic drugs enter the market once the patent protection of the original developer expires. Generally, the cost of generic drugs is 50-70 percent lower than that of their brand-name counterparts, while meeting the very same standards of safety, quality, and efficacy as the innovator drugs. Generic drugs help the manufacturer by eliminating the need to develop and market a new drug. As the patent approaches expiration, manufacturers can apply to the FDA for approval to manufacture and sell generic versions of the drug. Generic drugs are equal to and within the bioequivalence range of branded drugs.
TechNavio's analysts forecast the Generic Drugs market in Japan to grow at a CAGR of 8.16 percent over the period 2014-2019.
Covered in this Report
The Generic Drugs market in Japan can be divided into three segments: Generic Prescription Medicines, Super Generics, and Biosimilars. This report covers the present scenario and the growth prospects of the Generic Drugs market in Japan for the period 2015–2019. To calculate the market size, the report considers the revenue generated from the following segments:
• Generic Prescription Medicines
• Super Generics
• Biosimilars
TechNavio's report, the Generic Drugs market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the Generic Drugs market in Japan and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Vendors
• Meiji Seika Pharma
• Nichi-Iko Pharmaceutical
• Nipro Pharma
• Sawai Pharmaceuticals
• Teva Pharmaceutical Industries
• Towa Pharmaceutical
Other Prominent Vendors
• Actavis
• Daiichi Sankyo
• Daito Pharmaceutical
• Eisai
• Fuji Pharma
• GlaxoSmithKline
• Hikari Pharmaceutical
• Hospira
• Mylan
• Nihon Generic
• Nippon Chemipher
• Nippon Kayaku
• Nissin Pharmaceutical
• Ohara Pharmaceutical
• Pfizer
• Sandoz
• Taiyo Yakuhin
• Takeda Pharmaceutical
• Zensei Pharmaceutical Industries
Market Driver
• Increase in Number of Patent Expiries
• For a full, detailed list, view our report.
Market Challenge
• Intense Competition among Vendors
• For a full, detailed list, view our report
Market Trend
• Increase in M&A
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Country Overview of Japan
07. Approval Pathway of Generic Drugs in Japan
07.1 Master File Scheme for Active Ingredients
07.2 Equivalency Review
07.3 Conformity Audit
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Product Category
10. Market Segmentation by Therapeutic Application
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Meiji Seika Pharma
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Revenue by Business Segmentation
19.1.6 Revenue Comparison 2011 and 2012
19.1.7 Revenue by Geographical Segmentation
19.1.8 Key Information
19.1.9 SWOT Analysis
19.2 Nichi-Iko
19.2.1 Key Facts
19.2.2 Business Description
19.2.3 Business Segmentation
19.2.4 Business Strategy
19.2.5 Revenue by Business Segmentation
19.2.6 Revenue Comparison 2011 and 2012
19.2.7 Revenue by Geographical Segmentation
19.2.8 Key Information
19.2.9 SWOT Analysis
19.3 Nipro Pharma
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Business Strategy
19.3.5 Revenue by Business Segmentation
19.3.6 Revenue Comparison 2011 and 2012
19.3.7 Revenue by Geographical Segmentation
19.3.8 Key Information
19.3.9 SWOT Analysis
19.4 Sawai
19.4.1 Key Facts
19.4.2 Business Description
19.4.3 Business Segmentation
19.4.4 Business Strategy
19.4.5 Revenue by Business Segmentation
19.4.6 Revenue Comparison 2011 and 2012
19.4.7 Revenue by Geographical Segmentation
19.4.8 Key Information
19.4.9 SWOT Analysis
19.5 Teva Pharmaceutical Industries
19.5.1 Key Facts
19.5.2 Business Description
19.5.3 Business Segmentation
19.5.4 Business Strategy
19.5.5 Revenue by Business Segmentation
19.5.6 Revenue Comparison 2011 and 2012
19.5.7 Revenue by Geographical Segmentation
19.5.8 Key Information
19.5.9 SWOT Analysis
19.6 Towa Pharmaceutical
19.6.1 Key Facts
19.6.2 Business Description
19.6.3 Business Segmentation
19.6.4 Business Strategy
19.6.5 Revenue by Business Segmentation
19.6.6 Revenue Comparison 2011 and 2012
19.6.7 Revenue by Geographical Segmentation
19.6.8 Key Information
19.6.9 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Country Overview of Japan
Exhibit 3: Main Data Required for Generic Drugs Approval
Exhibit 4: Generic Drugs Market in Japan Overview
Exhibit 5: Generic Drugs Market in Japan 2014-2019 (US$ billion)
Exhibit 6: Parameters to Promote the Use of Generic Drugs Ahead
Exhibit 7: Generic Drug Market Share of Japan in 2014 (in percent)
Exhibit 8: Generic Drugs Market Share of Japan in 2019 (in percent)
Exhibit 9: Generic Drugs Market Share of Japan and Global (US$ billion)
Exhibit 10: Generic Drugs Market Segmentation by Product Category
Exhibit 11: Generic Drugs Market in Japan by Therapeutic Applications
Exhibit 12: Patent Expiration of Branded Drugs in Japan
Exhibit 13: Medical Costs in Japan (in thousand billion)
Exhibit 14: Price Difference of atorvastatin between Originator and Generic in Japan (US$)
Exhibit 15: Trends of Aging Population in Japan (in percentage)
Exhibit 16: Reviews Conducted for Generic Drugs and Others by Fiscal Year 2008-2012
Exhibit 17: Comparison between Applications Filed and Approval in Japan
Exhibit 18: Meiji Seika Pharma: Business Segmentation by Revenue 2013
Exhibit 19: Meiji Seika Pharma: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 20: Meiji Seika Pharma: Geographical Segmentation
Exhibit 21: Nichi-Iko: Business Segmentation by Revenue 2013
Exhibit 22: Nichi-Iko: Business Segmentation by Revenue 2012 and 2013
Exhibit 23: Nichi-Iko: Geographical Segmentation by Revenue 2013
Exhibit 24: Nipro Pharma: Business Segmentation by Revenue 2013
Exhibit 25: Nipro Pharma: Business Segmentation by Revenue 2012 and 2013
Exhibit 26: Nipro Pharma: Geographical Segmentation by Revenue 2013
Exhibit 27: Sawai: Business Segmentation by Revenue 2013
Exhibit 28: Sawai: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 29: Sawai: Geographical Segmentation
Exhibit 30: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2013
Exhibit 31: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2012 and 2013
Exhibit 32: Teva Pharmaceutical Industries: Geographical Segmentation by Revenue 2013
Exhibit 33: Towa Pharmaceutical: Business Segmentation by Revenue 2013
Exhibit 34: Towa Pharmaceutical: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 35: Towa Pharmaceutical: Geographical Segmentation
